January 7, 2019 / 1:25 PM / 3 months ago

BRIEF-Xencor Regains Ex-U.S. Commercial Rights To Xmab®13676, Cd20 X Cd3 Bispecific Antibody

Jan 7 (Reuters) - Xencor Inc:

* XENCOR REGAINS EX-U.S. COMMERCIAL RIGHTS TO XMAB®13676, CD20 X CD3 BISPECIFIC ANTIBODY

* XENCOR INC - INITIAL DATA FROM ONGOING PHASE 1 STUDY IN PATIENTS WITH B-CELL MALIGNANCIES EXPECTED IN 2019

* XENCOR INC - CO, NOVARTIS TO CONTINUE CO-DEVELOPING XMAB14045, A CD123 X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below